Journal article

What is the impact of biologicals in colorectal cancer?

Rachel Wong, David Cunningham

Targeted Oncology | SPRINGER | Published : 2008

DOI: 10.1007/s11523-008-0074-9

University of Melbourne Researchers

Keywords

1st-Line Treatment
Oxaliplatin
Vegf
Phase-Ii Trial
Growth-Factor Receptor
Oncology
Bevacizumab
Kras Mutation
Biological Agents
Cetuximab
Tyrosine Kinase Inhibitor
Leucovorin
Colorectal Cancer
Life Sciences & Biomedicine
Science & Technology
Antibody Therapy
Plus Irinotecan
Egfr